<DOC>
	<DOC>NCT00637091</DOC>
	<brief_summary>The purpose of this study is to investigate the response rate of cetuximab plus irinotecan every 2 weeks in patients harboring wild-type KRAS with and without detectable EGFR-expressing metastatic CRC after failure to irinotecan in an exploratory manner.</brief_summary>
	<brief_title>Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions</brief_title>
	<detailed_description>Twenty patients with positive-EGFR results and 20 patients with negative-EGFR results will be accrued in this study. All patients should have wild-type KRAS.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Colorectal adenocarcinoma, Wild KRAS, 1875 yr Estimated life expectancy of more than 3 months ECOG performance status of 0 to 1 at study entry Adequate bone marrow function Adequate liver function Documented progression during or within 3 months of irinotecancontaining regimens as a firstline chemotherapy Immunohistochemical evidence of a presence or absence of EGFR expression by PharmDx Kit Informed Consent Central nervous system (CNS) metastases or prior radiation for CNS metastases. Intestinal obstruction or impending intestinal obstruction due to peritoneal carcinomatosis Surgery (excluding biopsy for diagnosis) during 4 weeks prior to inclusion in the study. Evidence of gastrointestinal bleeding Exposure to Cetuximab Prior administration of monoclonal antibodies, EGFR signal transduction inhibitors or EGFRtargeted treatment KRAS mutant Status Patients with serious toxicity to previous irinotecanbased chemotherapy Other serious illness or medical conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>